No Data
No Data
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion
Express News | Silexion Therapeutics Corp - to Conduct Additional Toxicology and Pharmacodynamic Studies in 2025
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Trump's Tariff Moves: Market Stabilization Amid Uncertainty and the Road Ahead
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $5
Silexion Announces Completion Of SIL204 Development Plan For KRAS Cancers; Presentation Scheduled At NeauxCancer 2025 Conference In New Orleans